SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is driving significant community debate as traders split between those chasing high-volatility meme coin gains and others warning of a potential rug pull or scam. While some proponents highlight its unique structure and rapid momentum as signs of a breakout, skeptics are actively pointing to its low holder count and lack of fundamental utility.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing significant volatility as investors debate the impact of geopolitical tensions in the Middle East against the backdrop of an aggressive AI-driven supercycle. While community members highlight robust earnings and long-term demand for HBM chips as a potential floor for the stock, ongoing confusion surrounding potential U.S.-Iran diplomatic talks has led to intense short-term selling and widespread speculation about institutional market manipulation.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing extreme volatility and intense community interest following its NYSE debut, driven by its access to high-profile private tech holdings like Anthropic and SpaceX. Investors are actively debating the sustainability of the stock's massive premium over its net asset value, fueled by a restricted float due to a six-month lockup period that prevents early shareholders from selling.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is currently trending due to unconfirmed, high-volume market activity and persistent speculation regarding a potential M&A event. Community discussions are heavily focused on the stock's significant after-hours volume and historical parallels to recent biotech buyouts, with many investors debating the plausibility of a deal while weighing the company's established commercial growth against long-term pipeline potential.

Merlin, Inc. is an aerospace and defense technology company focused on developing autonomous flight solutions. The company is building an operating system of record for autonomous aviation, with its Merlin Pilot system enabling a wide range of aircraft and mission profiles. Its technology has been validated through hundreds of autonomous flights conducted at test facilities worldwide. The company is headquartered in Boston, MA.

Merlin Inc.

Marlin Business Services Corp.

Marlin Business Services is currently a focal point for investors due to significant confusion surrounding its identity, with many traders debating whether the ticker refers to the historical financial services firm or the newly public Merlin Inc. in the AI aviation sector. The community is actively discussing the stock's potential for momentum-driven moves and high-volatility spikes, while many retail participants remain focused on the recent transition from a special purpose acquisition company.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is experiencing intense volatility and downward pressure as investors rotate out of gold, which has lost its traditional safe-haven status amid the ongoing Iran-U.S. conflict. The community is actively debating whether this represents a long-term capitulation or a temporary liquidity flush, with many retail traders expressing frustration over the asset's recent performance compared to tech and equity markets.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is attracting significant community attention as traders debate whether current volatility surrounding Middle Eastern geopolitical tensions justifies a bullish position or represents a trap in a fundamentally decaying asset. While some investors are betting on a major spike driven by potential energy infrastructure disruptions and broader market uncertainty, others are actively warning against holding the ETF long-term, advocating for shorting or buying puts on any upward price bounces.

The Estée Lauder Companies, Inc. engages in the manufacture of skin care, makeup, fragrance and hair care products. It sells products under Estée Lauder, Clinique, Origins, MAC, Bobbi Brown, La Mer, Jo Malone London, Aveda and Too Faced. The company was founded by Estee Lauder and Joseph Lauder in 1946 and is headquartered in New York, NY.

Estee Lauder Cos., Inc. - Ordinary Shares - Class A

Estee Lauder Cos. Inc

Estee Lauder (EL) shares are currently seeing significant volatility and investor chatter as the market reacts to ongoing merger talks with Spanish beauty powerhouse Puig, while the company concurrently navigates a challenging turnaround plan. The community is sharply divided, with many debating whether the stock represents a deep-value opportunity in luxury beauty or if it remains trapped by restructuring hurdles, negative income, and broader headwinds from international tariffs.

"Cryptocurrency is a scam" - it would be ironic if something called a scam made everyone rich.

ScamToken

ScamToken is capturing intense attention as the crypto community debates whether it is a transparent social experiment, a satirical commentary on pump-and-dump schemes, or just another risky asset. Users are actively questioning the project's legitimacy and long-term viability while simultaneously using the ticker as a platform to voice broader frustrations with market volatility and high-profile speculative ventures.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is currently at the center of polarized debate following its board's approval of a 5-for-1 stock split, which bulls view as a catalyst for increased retail accessibility and liquidity, while bears characterize it as a tactical move to mask underlying fundamental weaknesses. Community sentiment remains intensely divided between investors betting on a continued parabolic trajectory and those anticipating a structural collapse, with active discussions focusing on high-level insider selling, subprime loan delinquency concerns, and the impact of the stock's S&P 500 inclusion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech stocks remain a hot sector for retail traders on Stocktwits,&nbsp;which collectively boast over 3.45 million followers.&nbsp;In January, several biotech names saw explosive gains as investors bet on breakthrough treatments, key partnerships, and regulatory milestones.According to Stocktwits data, these five biotech stocks saw the highest surge in retail following this month.CARGO Therapeutics Inc. (CRGX) – 445% Jump In FollowersCARGO Therapeutics, a clinical-stage biotech company focused on cancer treatments, saw its stock collapse even as retail interest surged.&nbsp;In January, the FDA cleared its Investigational New Drug (IND) application for CRG-023, a novel tri-specific CAR T therapy designed to tackle relapse factors in B-cell malignancies.&nbsp;However, the company later announced it would discontinue a Phase II trial of its lead candidate, firi-cel, after an ad hoc safety analysis revealed an unfavorable benefit-risk profile.&nbsp;Wall Street analysts issued downgrades, and CARGO’s stock is on track to plunge more than 76% in January — its worst month since going public in November 2023.&nbsp;Short interest stands at 15.1%, according to Koyfin data.Sana Biotechnology Inc. (SANA) – 185% Jump In FollowersSana Biotechnology, which focuses on engineered cell therapies, captured investor attention with a potential&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-triples-after-type-1-diabetes-trial-data/chGBWsVRZO">breakthrough</a> in type 1 diabetes.&nbsp;The company demonstrated earlier this month that its hypoimmune edits allowed islet cell transplant survival without immunosuppression.&nbsp;Analysts praised the findings, driving the stock up roughly 114% in January — its best month since its March 2021 market debut.&nbsp;Short interest is at 16.6%.Silexion Therapeutics Corp. (SLXN) – 92% Jump In FollowersSilexion, an oncology-focused biotech developing RNA interference therapies, gained momentum after releasing preclinical data on a second-generation siRNA candidate, SIL-204.&nbsp;The treatment&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/slxn-stock-hits-record-low-after-pricing-5m-offering/chGtwKoRng">showed</a> synergistic efficacy when combined with first-line chemotherapy for pancreatic cancer.&nbsp;Although the stock gained just 2% in January, it marked its best month since November.&nbsp;Short interest remains low at 2.4%.AEON Biopharma Inc. (AEON) – 81% Jump In FollowersAEON Biopharma is developing ABP-450, a botulinum toxin complex similar to Evolus’ Jeuveau, for medical indications such as chronic migraine.&nbsp;Retail traders appeared to buy the dip after AEON priced a $20 million public offering earlier this month, which initially sent shares tumbling.&nbsp;The stock is headed for a 77% drop in January, its worst month since going public via a SPAC merger in July 2023.&nbsp;Short interest is just 0.2%, according to Koyfin.Kairos Pharma (KAPA) – 78% Jump In FollowersKairos Pharma, a clinical-stage biopharmaceutical company, saw retail interest soar this month after breaking key resistance levels and securing crucial investments.&nbsp;The company is testing its lead candidate, ENV105 — which targets a protein linked to resistance in cancer treatments — in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.The stock gained momentum following CEO John Yu’s positive comments at an investor healthcare summit this month and the completion of a $3.5 million PIPE transaction.&nbsp;Kairos shares are set to decline 2.6% in January, marking their worst month since October.&nbsp;Short interest remains&nbsp;negligible at 0.1%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.

Equity

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.


The biotech sector remains a hotbed for retail investor interest, with over 3.4 million users following these stocks on Stocktwits. Last week, the below three companies saw the highest increases in retail following:Kairos Pharma Ltd. (+83%)Kairos Pharma, a clinical-stage biopharmaceutical company focused on cancer therapeutics, saw the most spike in retail chatter.&nbsp;The company is testing its lead candidate, ENV105 — which targets a protein linked to resistance in cancer treatments — in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.Retail interest soared last week after Kairos broke key resistance levels and secured crucial investments.&nbsp;The stock surged nearly 120% last Monday following positive comments from CEO John Yu at an investor healthcare summit.&nbsp;Additionally, the company completed a $3.5 million PIPE transaction, which the CEO said would ensure the continued progress of its clinical trials and asset development.&nbsp;Despite these gains, Kairos has lost 21% of its value since its NYSE debut in September.OS Therapies Inc. (+39%)Shares of OS Therapies jumped after the company reported positive clinical trial data for its OST-HER2 candidate, which targets a rare bone cancer that spreads to the lungs.&nbsp;Following the announcement, Maxim analyst Jason McCarthy raised the firm’s price target to $15 from $8, maintaining a ‘Buy’ rating.&nbsp;The data has positioned OS Therapies to meet with the FDA by the end of the first quarter of 2025 to discuss the possibility of filing for accelerated approval.The company is focused on oncology treatments, with OST-HER2 being its lead immunotherapy asset. It leverages listeria bacteria’s immune-stimulatory effects to target the HER2 protein in cancer cells.AEON Biopharma Inc. (+19%)AEON Biopharma is a company developing the proprietary botulinum toxin complex ABP-450, a biosimilar to Evolus’ Jeuveau, approved for cosmetic use, but AEON is developing it for medical indications.&nbsp;The company’s manufacturing partner, Daewoong, produces ABP-450 in FDA-approved facilities under current Good Manufacturing Practices (cGMP).Although there were no specific catalysts driving the recent spike, it appears that retail investors were buying the dip after the company priced a public offering to raise $20 million earlier this month, which had caused the stock to slide.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kairos, OS Therapies, AEON See Highest Weekly Spike In Retail Following Among Biotechs: Here's Why

Cancer treatments, FDA breakthroughs, and other developments fueled a sharp spike in interest for these biotech players, as investors bet on promising clinical data and strategic moves.

Cryptocurrencies were on fire last week and therefore it should come as no surprise that Stocktwits users turned their attention increasingly toward the crypto and allied space. Among the 10 stocks that saw the biggest increase in watcher count on Stocktwits, four were cryptocurrencies and two were Bitcoin miners.Here’s a compilation of stocks/cryptos that were closely followed by retail last week along with their watcher count:<ul><li>Dogecoin (<a class="mention" data-mention="$DOGE.X" data-symbol-id="DOGE.X" href="https://stocktwits.com/symbol/DOGE.X" target="_blank">$DOGE.X</a>) (336,178)</li><li>SPDR S&amp;P 500 ETF Trust (<a class="mention" data-mention="$SPY" data-symbol-id="SPY" href="https://stocktwits.com/symbol/SPY" target="_blank">$SPY</a>) (537,941)</li><li>Bitcoin (<a class="mention" data-mention="$BTC.X" data-symbol-id="BTC.X" href="https://stocktwits.com/symbol/BTC.X" target="_blank">$BTC.X</a>) ($601,174)</li><li>Ripple (<a class="mention" data-mention="$XRP.X" data-symbol-id="XRP.X" href="https://stocktwits.com/symbol/XRP.X" target="_blank">$XRP.X</a>) (174,221)</li><li>Innovation Beverage Group Ltd. (<a class="mention" data-mention="$IBG" data-symbol-id="IBG" href="https://stocktwits.com/symbol/IBG" target="_blank">$IBG</a>) (1,260)</li><li>Tesla, Inc. (<a class="mention" data-mention="$TSLA" data-symbol-id="TSLA" href="https://stocktwits.com/symbol/TSLA" target="_blank">$TSLA</a>) (980,127)</li><li>PepeCoin (<a class="mention" data-mention="$PEPE.X" data-symbol-id="PEPE.X" href="https://stocktwits.com/symbol/PEPE.X" target="_blank">$PEPE.X</a>) (17,692)</li><li>Kairos Pharma Ltd. (<a class="mention" data-mention="$KAPA" data-symbol-id="KAPA" href="https://stocktwits.com/symbol/KAPA" target="_blank">$KAPA</a>) (1,076)</li><li>Mara Holdings Ltd. (<a class="mention" data-mention="$MARA" data-symbol-id="MARA" href="https://stocktwits.com/symbol/MARA" target="_blank">$MARA</a>) (147,043)</li><li>BTC Digital Ltd. (<a class="mention" data-mention="$BTCT" data-symbol-id="BTCT" href="https://stocktwits.com/symbol/BTCT" target="_blank">$BTCT</a>) (4,228)</li></ul>Dogecoin:&nbsp;Dogecoin, a meme coin, was on a tear last week as it went past the $0.40 level before pulling back since the mid-week. The retail crowd are factoring in the meme crypto breaking above its May 2021 highs of $0.74.&nbsp;SPY: The SPY, which is an exchange-traded fund that tracks the broader S&amp;P 500 Index, closed at a record high of $598.76 last Monday. The ETF has come under pressure since then amid fears that the Federal Reserve may give rate cuts a pass at the December meeting. As the year draws to the close and the market enters a seasonally strong period, retail interest in the ETF has been on the rise.Bitcoin:&nbsp;Donald Trump’s victory in the Nov. 5 election has set in motion broad-based buying in the crypto space amid hopes his policies would be more crypto-friendly. Bitcoin rose to a record high past the $93K level last week before pulling back to the $90K level. It has started the new week on a firmer note and has rebounded toward the $92K level.Ripple: Blockchain company Ripple’s native coin, the XRP, rallied past the $1 against the U.S. dollar last week amid hopes that SEC Chair Gary Gensler would be replaced. The current SEC Chair has gone after Ripple and the regulator has an ongoing lawsuit against the company for raising&nbsp;more than $1.3 billion in 2013 by selling XRP in an unregistered public offering.&nbsp;Innovation Beverage: Australian beverage maker Innovation Beverage, which sells domestically and in the U.S., saw its Nasdaq-listed shares jump 40% last week. The gains have been accompanied by a surge in volumes traded. Following a recent initial public offering, the stock was listed on Sept. 26.Retailers on the Stocktwits see scope for further upside as some of them pointed to the stock being a subject of interest on WallStreetBets reddit forum.Tesla: Trump’s victory led to a surge in Tesla shares past the $350 mark (on an intraday basis) last week but they have pulled back since then. Tesla investors view Elon Musk’s closeness to Trump as a positive for the stock even as the company’s electric-vehicle business is awaiting an inflection.PepeCoin:&nbsp;PepeCoin, another meme coin that has generated interest among retailers, more than doubled in the seven sessions that ended Nov. 9, coinciding with the presidential election. It topped $5 on Nov. 9 but has retreated since then and traded around the $4 mark.&nbsp;&nbsp;Kairos Pharma: Shares of California-based nano-cap oncology-focused clinical-stage biotech Kairos surged past $2 on Tuesday on above-average volume, with retail frenzy propping up the stock.. The buying continued in the next session before moderating. Kairos is a newly public company and was listed in mid-September.&nbsp;Mara Holdings:&nbsp;Bitcoin miner Mara’s shares plunged on Wednesday after the company reported a third-quarter revenue miss. Retail, however, is betting on the company in the hopes that the Bitcoin rally could help the miner stage a comeback.BTC Digital:&nbsp; BTC Digital shares soared over 950% to $19.27 in the week ended Nov. 15, rising from under $2 in the previous week. Retailers on the Stocktwits are bullish on the bitcoin miner.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/10-stocks-with-biggest-message-volume-on-stocktwits/cJ4HwPIRQP">10 Most Active Stocks On Stockwits Last Week With Message Volume Spurt</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

Trump trades have continued to evince retail attention. 

10 Stocks/Cryptos With Biggest Increases In Followers On Stocktwits Last Week

Dogecoin, SPY, Bitcoin, Ripple and Innovation Beverage were among the securities that drew retail attention last week.

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. It focuses on the research and development of immunotherapies for oncology. The company was founded by John S. Yu on June 17, 2013 and is headquartered in Los Angeles, CA.

KAPA
Kairos Pharma Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest KAPA News

KAPAKairos Pharma Ltd.